Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
Снижение заболеваемости сахарным диабетом 2 типа при изменении образа жизни или приеме метформина
2002-02-07
SCID: 54.1/hs3w2gsh
Discuss with AI
Type 2 diabetes preventionincidence reductionlifestyle interventionmetforminrandomized trial
Figures from the paper
Abstract (AI)
BACKGROUND: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. METHODS: We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups. RESULTS: The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. CONCLUSIONS: Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.
Key Findings
1
In a randomized trial of 3234 high-risk, non-diabetic adults, lifestyle intervention reduced diabetes incidence to 4.8 cases per 100 person-years versus 11.0 with placebo.
2
Lifestyle intervention reduced diabetes incidence by 58% (95% CI, 48 to 66%) compared with placebo.
3
Lifestyle intervention was significantly more effective than metformin in preventing or delaying diabetes.
4
Metformin (850 mg twice daily) reduced diabetes incidence to 7.8 cases per 100 person-years, a 31% reduction (95% CI, 17 to 43%) versus placebo.
5
Number needed to treat over three years: 6.9 persons for lifestyle intervention and 13.9 persons for metformin to prevent one case of diabetes.
Research Object
High-risk nondiabetic adults with elevated fasting and post-load plasma glucose concentrations (participants in the clinical trial)
Research Subject
Effect of a lifestyle-intervention program versus metformin (850 mg twice daily) on the incidence (prevention/delay) of progression to type 2 diabetes
Publication Details
Publication Date
2002-02-07
Journal
Publisher
ISSN
Cited by
19364
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by20
Diagnosis and Classification of Diabetes Mellitus2010
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement2005
Health benefits of physical activity: the evidence2006
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2019
Prevalence and Trends in Obesity Among US Adults, 1999-20002002
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
Diagnosis and Classification of Diabetes Mellitus2009
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2019
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—20222021
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 20212023
Standards of Medical Care in Diabetes—20132012
European Guidelines for Obesity Management in Adults2015
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Standards of Medical Care in Diabetes—20122011
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2013
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction2007
Exercise and Type 2 Diabetes2010
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease2020